Expanding the reach of antibody therapeutics
Determined to revolutionize the reach of cancer treatment by developing potent and precise therapies that can target the entire universe of cancer antigens.
Why Crossbow
We aim to cure cancer. Our team is urgently working to create an arsenal of therapeutics that expands the reach and impact of antibodies used to treat cancer.
We chose the name Crossbow because our next-generation therapies embody the precision and power of a crossbow. With unparalleled accuracy and potency, our T-Bolt™ molecules strike tumor cells like a crossbow shoots bolts at its target.
Join us on our bold quest to broaden the benefits of immunotherapy and improve the lives of people living with cancer.
What we do
Selecting from the expanding universe of cancer antigens
We identify, validate and prioritize the most promising cancer antigens for our T-Cell Receptor mimetic (TCRm) discovery efforts.
Creating high-quality TCR-mimetics
Using a proprietary technology engine, we develop highly potent, highly accurate antibodies, targeting tumor-specific peptides presented by Major Histocompatibility Complex (MHC), thus mimicking T-Cell Receptors (TCRs).
Developing innovative products
Crossbow’s TCRm antibodies are incorporated into easy-to-assemble T-Cell engagers and other immunotherapies, optimizing manufacturability and potency, and minimizing tumor resistance.
Who we are
A team of international, collaborative and experienced inventors, drug developers and company builders. We value scientific excellence, passion, integrity, innovation, transparency, respect and accountability. We embrace problems deemed impossible to solve.
Hit your next career target at Crossbow!
-
Senior Director/Head of QA: Learn more
-
Senior Scientist/Principal Scientist, Biology: Learn more
News & Media
Keep up to date with everything happening at Crossbow.
March 5, 2024
Crossbow Therapeutics Selects First Development Candidate from its Portfolio of Next-Generation T-cell Engagers Directed at Intracellular Cancer Targets
July 11, 2023
Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class of Antibody Therapies That Mimic T-Cell Receptors to Treat Cancer
Contact Us
